What is Veravas?
Veravas is at the forefront of transforming laboratory diagnostics, leveraging its proprietary VeraBIND technology. This patented system is engineered to significantly enhance the detection of low-abundance biomarkers, a critical advancement for early disease detection. The company's solutions, exemplified by the VeraBIND Tau assay, are specifically designed to identify tau pathology linked to Alzheimer's disease. Veravas provides advanced research solutions to clinicians, researchers, and payers, aiming to improve assay sensitivity and reliability across a spectrum of diseases. Their commitment lies in accelerating research and refining diagnostic accuracy through cutting-edge sample preparation and analysis techniques.
How much funding has Veravas raised?
Veravas has raised a total of $4.3M across 3 funding rounds:
Unspecified
$4M
Debt
$150K
Debt
$198K
Unspecified (2020): $4M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Debt (2021): $198K supported by PPP
Key Investors in Veravas
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Veravas?
With the recent major strategic investment, Veravas is poised for accelerated growth and further development of its diagnostic technologies. The substantial enterprise-level funding suggests a strategic focus on scaling operations, expanding market reach, and potentially advancing its VeraBIND technology through clinical trials and regulatory approvals. This capital infusion will likely empower Veravas to enhance its assay sensitivity and reliability, solidifying its position in the competitive landscape of early disease detection and Alzheimer's diagnostics. The company's trajectory indicates a strong potential for future innovation and market impact.
See full Veravas company page
